Dr. Sulaiman Al Habib Medical Services Groupسليمان الحبيب
- Price
- 218.70 SAR
- Fair value
- 64.53 SAR
- Discount to fair value
- −239%
- Mkt cap
- 76.55B
- P/E
- 31.9×
- P/B
- 9.69×
- EV
- 83.57B
- Div yield
- 2.17%
- ROE
- 30.4%
- Net margin
- 17.5%
Current price218.7SAR
Fair value (est., median)64.53SAR
UndervaluedFair valueOvervalued
+238.9% above fair valueWould need to fall ~70.5% to reach fair value.
Median ofDCF 60.82DDM 70.75Graham 58.67Residual Income 81.32Earnings Power 64.53
Health Check
46.6
Overall / 100
Good (66+)Caution (40–65)Risk (<40)
Rewards
- Strong return on equity (30.4%).
Risks
- Trades 238.9% above estimated fair value.
- Expensive on book (P/B 9.7×).
Scores are computed automatically from the real financial statements (Value from fair value; the rest from growth, profitability, balance sheet and dividends). A decision aid, not investment advice.
Price, corporate actions & news
Demo series
D — DividendS — Split▲ good · ▼ bad newstap a marker for detailsDemo series
Growth & profitability
Revenue, net income and margin.
RevenueNet incomeNet margin %tap a bar for figures
Key figures
Covers 4 years · FY2022–FY2025
| Metric | FY'22 | FY'23 | FY'24 | FY'25 | TTM'26 |
|---|---|---|---|---|---|
| Revenue | 8.31B | 9.51B | 11.20B | 13.71B | — |
| Net Income | 1.65B | 2.05B | 2.32B | 2.40B | 2.35B |
| Net Margin | 19.9% | 21.5% | 20.7% | 17.5% | — |
| Operating Cash Flow | 2.84B | 3.24B | 2.97B | 3.40B | — |
| OCF Margin | 34.2% | 34.1% | 26.5% | 24.8% | — |
| Capital Expenditure | 1.51B | 3.50B | 3.83B | 2.98B | — |
| Free Cash Flow | 1.33B | -252.74M | -858.19M | 418.64M | — |
| FCF Margin | 16.0% | -2.7% | -7.7% | 3.1% | — |
| FCF Conversion | 80.6% | -12.4% | -37.1% | 17.4% | — |
| EPS (Diluted) | 4.72/sh | 5.85/sh | 6.62/sh | 6.86/sh | 6.71/sh |
| Dividend / Share | 3.25/sh | 4.10/sh | 4.69/sh | 4.75/sh | — |
Dividend return (if you buy today)if you buy today
Dividend yield2.17%
Dividend / share4.75
If you invest
Shares (≈)45
Est. annual income213.75
At this rate, dividends alone return your capital in ~46.0 years.
Dividend history
Dividend / share & historical yield (SAR).
Dividend / share yield %tap a bar for figures
Quarterly dividends & yield
Per-share dividends by quarter, full-year total, and yield on the year's average price · SAR
| Year | Q1 | Q2 | Q3 | Q4 | Full year | Yield (avg) |
|---|---|---|---|---|---|---|
| 2026 | — | — | — | — | — | — |
| 2025 | — | — | — | — | 4.75 | — |
| 2024 | — | — | — | — | 4.69 | — |
| 2023 | — | — | — | — | 4.10 | — |
| 2022 | — | — | — | — | 3.25 | — |
Valuation breakdown
Fair value = median of the applicable methods (DCF، DDM، Graham، Residual Income، Earnings Power).
Each method below is a different lens on the same company — no single method dominates the result.
Discounted Cash Flow
Values the company from the future cash it's expected to generate. · Tap to adjust assumptions
60.82
Dividend Discount Model
Values the share from the dividends it's expected to keep paying. · Tap to adjust assumptions
70.75
Graham Number
A conservative benchmark built from earnings and book value. · Tap to adjust assumptions
58.67
Residual Income (justified P/B)
Values the profit the company earns above the cost of its equity. · Tap to adjust assumptions
81.32
Earnings Power Value
Values today's earning power as-is, assuming no growth. · Tap to adjust assumptions
64.53
DCF only is anchored on FY2025 — the latest year with positive cash flow that supports a value. The other methods (DDM, Graham, RIM, EPV) use current / normalized figures.
Fair Value (median)64.53
▸ Show assumptions▾ Assumptions
- Effective discount rate
- 9.92%
- CAPM cost of equity
- 10.50%
- Risk-free rate
- 4.50%
- Equity risk premium
- 6.00%
- DCF growth (stage 1)
- 8.00%
- DCF terminal growth
- 3.00%
- DCF forecast years
- 5
- DDM dividend growth
- 3.00%
Tune these per company in the Hajras Odoo backend; values recompute automatically.
Analyst Price Targets
1 houseHistorical — last published analyst views, not a current target.
Hajras fair value: 64.53
Aljazira Capital
as of 2022-10-24 · Dr. Sulaiman AlHabib Medical Services Group - Results Flash Note Q3-22
Hold
193.00
—
Forward guidance & context
No explicit numeric revenue-growth target from management. Derived from the disclosed expansion pipeline: ~2,000 beds added across 6 hospitals in 2024-2025 (sector-leading ~3,500 beds) plus 5+ hospitals under construction (Tabuk, Jubail, Red Sea, AMAALA, Munsiyah, Dammam) targeting end-2027/2028. Anchored to Al Jazira Capital's FY24-29E revenue CAGR of ~13.2% (net-income CAGR ~17%), reaching ~20.8bn revenue by FY29E. Near-term is faster (FY25 actual +22.4%; FY26E ~20-27% per analysts) as ramp-ups complete; ~13% is the defensible mid-cycle figure.
Management-guided scenario (not the headline fair value)
guided growth: 13%(reasoned from expansion plans)
guided DCF: 1.65
vs base case 60.82
price 218.70
Re-runs the DCF at the guided growth to show the upside if management's plans land. The headline fair value stays grounded in reported numbers.
- 2026-02-17
HMG's official FY2025 investor presentation confirms a multi-hospital pipeline under construction with stated opening targets: Tabuk, Jubail Industrial City and Red Sea hospitals, plus AMAALA, Munsiyah (Riyadh) and Dammam hospitals targeted for end of 2027/2028. This extends the aggressive 2024-25 expansion wave (six new hospitals, ~2,000 beds added) and underpins continued double-digit revenue growth.
HMG FY2025 Investor Presentation (official IR) - 2026-02-15
FY2025 results (Saudi Exchange disclosure): revenue rose 22.4% YoY to 13.7bn (from 11.2bn) driven by the launch of six new hospitals in 2024-2025 and patient volumes up 28% to 9.46mn. However, net profit grew only 3.7% to 2,401mn as fixed costs, depreciation and financing from newly commissioned hospitals still in ramp-up compressed margins.
Sahm Capital / Saudi Exchange FY2025 results - 2026-05-03
Q1 2026: revenue grew 8.8% YoY to 3,436mn but net profit fell 9.6% to 503mn. Management attributed the profit decline to fixed costs, higher depreciation and financing costs from newly commissioned hospitals still in the ramp-up phase, plus Q1 seasonality. This is the key near-term risk for a valuation: aggressive expansion is dilutive to margins until new beds reach optimal occupancy.
Sahm Capital / Saudi Exchange Q1 2026 results - 2025-10-26
Al Jazira Capital (Overweight, TP 300) forecasts FY24-29E revenue CAGR of ~13.2% and net-income CAGR of ~17%, reaching ~20.8bn revenue and ~5.1bn net income by FY29E. Two further expansions remain (Tabuk 140 beds for FY27E; Jubail 145 beds, 571mn capex, for FY29E). FY25 is viewed as the trough for gross margins (~32.2%) before recovering toward 34.1% by FY27E as new facilities ramp.
Al Jazira Capital Q3-25 Flash Note & Sep-25 Investment Update
Sources
HMG FY2025 Investor Presentation (official IR, as of 17 Feb 2026) - pipeline & capacity HMG Investor Relations home Sahm Capital - HMG FY2025 results (2,401.47M net profit, revenue +22.4% to 13.7bn) Sahm Capital - HMG Q1 2026 results (503.29M net profit, revenue +8.8%, ramp-up margin pressure) Al Jazira Capital - HMG Q3-25 Results Flash Note (Oct 2025): FY25E rev 13,843mn +23.6%, TP 300 Al Jazira Capital - HMG Investment Update (Sep 2025): FY24-29E revenue CAGR 13.2% / net income CAGR 17%, Tabuk FY27E, Jubail FY29E ANB Capital - HMG Initiation of Coverage (bed capacity 1,913 → 3,609 by 2028, rev CAGR ~19% 2023-28) Argaam - Sulaiman Al Habib CFO: future projects financed through cash flow & Shariah-compliant loans Zawya - HMG spending 6.5bn (USD 1.73bn) on six new hospitals; North Riyadh 500 beds largest Zawya - HMG plans new hospital in Jubail Industrial City
Management guidance is not a promise; shown as context and a separate scenario. Not financial advice.
Wealth simulator
What if you'd invested in Dr. Sulaiman Al Habib Medical Services Group regularly?
Starting year
- Invested
- 1K/yr · 1K total(2026 → today · 1 yrs)
- your value today is
- 1K SAR
- Total return
- +2.2%(+2.2% Dividends · 0.0% Capital gain)
- Annualised (IRR)
- +4.9%
Invested1KSAR
Dividends22SAR
Capital gain0SAR
InvestedCapital gainDividendstap a bar for figures
Community Notes0
No notes yet. Be the first to share a thesis.